Professor Luigi Terracciano is Rector of Humanitas University and Scientific Director of Humanitas.
He is Full Professor of Anatomic Pathology and since September 2020, serves as the Head of the Anatomic Pathology Division at Humanitas University Hospital , Department of Biomedical Sciences, Rozzano (Milan), Italy.
Till August 2020 has served as the Head of the Molecular Pathology Division and Chair of Experimental Pathology at the Institute of Medical Genetics and Pathology, University Hospital Basel, Switzerland. After his medical degree, followed by residency in Anatomic Pathology at University Federico II of Naples, Italy, he was a postdoctoral fellow at the Max Planck Institute for Physiology in Heidelberg, Germany.
Since 1998, Prof. Terracciano is member of the International Liver Study Group, a panel of the most well-regarded liver pathologists in the world. In 2016, he received the Dora Seif Award for his contribution to research on liver cancer.
He has a long standing research interest in non-neoplastic and neoplastic gastrointestinal and hepatic diseases. In particular, Prof. Terracciano has 30 years of experience in molecular pathology, translational research and cancer bio-repositories, as well as high-throughput techniques such as tissue microarray, a tool developed in his laboratory.
His expertise is demonstrated by numerous publications focusing on the identification of prognostic and predictive biomarkers in various gastrointestinal and hepatic neoplastic diseases.
Within his Division of Molecular Pathology in Basel, some 1800 next generation sequencing (NGS) analyses of various neoplasia from patients from University Hospital Basel and, more frequently, from other hospitals in Switzerland, have been performed annually.
- Tornillo L, Carafa V, Richter J, Sauter G, Moch H, Minola E, Gambacorta M, Bianchi L, Vecchione R, Terracciano LM Marked genetic similarities between hepatitis-B-virus positive and hepatitis-C-virus positive hepatocellular carcinomas. Pathol., 192: 307-312; 2000
- Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hämmerle M, Tornillo L, Heim MH, Diederichs S, Cillo C, Terracciano LM, lncRNA HOTTIP / HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients., 59(3): 911-23; 2014
- Quagliata L, Quintavalle C, Lanzafame M, Matter MS, Novello C, di Tommaso L, Pressiani T, Rimassa L, Tornillo L, Roncalli M, Cillo C, Pallante P, Piscuoglio S, Ng CK, Terracciano LM High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Lab Invest., 98(1): 95-105, 2018
- Paradiso V, Garofoli A, Tosti N, Lanzafame M, Perrina V, Quagliata L, Matter MS, Wieland S, Heim MH, Piscuoglio S, Ng CKY, Terracciano LM, Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening. J Mol Diagn., 20(6): 836-848, 2018
- Hindupur SK, Colombi M, Fuhs SR, Matter MS, Guri Y, Adam K, Cornu M, Piscuoglio S, Ng CKY, Betz C, Liko D, Quagliata L, Moes S, Jenoe P, Terracciano LM, Heim MH, Hunter T, Hall MN, The protein histidine phosphatase LHPP is a tumour suppressor. Nature., 29; 555(7698): 678-682, 2018